Brief: Ocuphire Pharma Receives PDFUA Fee Waiver For Nyxol New Drug Application From FDA

Opus Genetics

12/09/2022 13:58

Sept 12 (Reuters) - Ocuphire Pharma Inc  OCUP.O :
    * OCUPHIRE PHARMA RECEIVES PDFUA FEE WAIVER FOR NYXOL NEW
DRUG
APPLICATION FROM FDA
    * OCUPHIRE PHARMA INC - REMAINS ON TRACK TO FILE NDA FOR
NYXOL IN
ITS FIRST INDICATION, REVERSAL OF MYDRIASIS (RM), IN LATE 2022
    * OCUPHIRE PHARMA INC - FDA) HAS GRANTED A SMALL BUSINESS
WAIVER
OF PRESCRIPTION DRUG USER FEE ACT FEE OF $3.1 MILLION FOR
505(B)(2) NDA FOR NYXOL

Source text for Eikon:  ID:nGNXbg6xCV 
Further company coverage:  OCUP.O 

 ((Reuters.Briefs@thomsonreuters.com;))